OncoMatch/Clinical Trials/NCT07025889

IBI343 Combined With Sintilimab Plus Chemotherapy in Gastric Cancer

Is NCT07025889 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including IBI343 and Sintilimab for gastric cancer.

Phase 1/2RecruitingRuijin HospitalNCT07025889Data as of May 2026

Treatment: IBI343 · Sintilimab · Oxaliplatin · S-1 — This is a Single-arm, Open-label, Phase 1b/2 Study of IBI343 Combined with Sintilimab Plus Chemotherapy in Previously Untreated, Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Check if I qualify

Extracted eligibility criteria

Cancer type

Gastric Cancer

Biomarker criteria

Required: CLDN18 CLDN18.2-positive

histopathologically confirmed CLDN18.2-positive disease

Required: HER2 (ERBB2) overexpression (IHC 3+, or IHC 2+ and positive by in situ hybridization)

HER2-positive (defined as immunohistochemistry [IHC] 3+, or IHC 2+ and positive by in situ hybridization) disease

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Cannot have received: topoisomerase inhibitor-based antibody-drug conjugate

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify